Bryn Mawr Trust CO Neurocrine Biosciences Inc Transaction History
Bryn Mawr Trust CO
- $5.44 Billion
- Q4 2024
A detailed history of Bryn Mawr Trust CO transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bryn Mawr Trust CO holds 3,676 shares of NBIX stock, worth $558,090. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,676
Previous 3,333
10.29%
Holding current value
$558,090
Previous $383,000
30.81%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
638Shares Held
93.8MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$2.15 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.52 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$782 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$391 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$283 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $14.5B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...